An innovative kinome platform to accelerate small-molecule inhibitor discovery and optimization from hits to leads. Issue 5 (May 2021)

• Record Type: Journal Article
• Authors: Chaudhry, Charu; Tebben, Andrew; Tokarski, John S.; Borzilleri, Robert; Pitts, William J.; Lippy, Jonathan; Zhang, Litao
• Is Part Of: Drug discovery today. Volume 26:Issue 5(2021)
• Page Start: 1115
• Page End: 1125
• Publication Date: 2021-05
• Subjects: Drugs -- Design -- Periodicals; Drugs -- Research -- Periodicals; 615.1
• DOI: 10.1016/j.drudis.2021.01.018
• Languages: English
• ISSNs: 1359-6446

Abstract

Abstract : Kinases, accounting for 20% of the human genome, have been the focus of pharmaceutical drug discovery efforts for over three decades. Despite concerns surrounding the tractability of kinases as drug targets, it is evident that kinase drug discovery offers great potential, underscored by the US Food and Drug Administration (FDA) approval of 48 small-molecule kinase inhibitors. Despite these successes, it is challenging to identify novel kinome selective inhibitors with good pharmacokinetic/pharmacodynamic (PK/PD) properties, and resistance to kinase inhibitor treatment frequently arises. A new era of kinase drug discovery predicates the need for diverse and powerful tools to discover the next generation of kinase inhibitors. Here, we outline key tenets of the Bristol Meyers Squibb (BMS) kinase platform, to enable efficient generation of highly optimized kinase inhibitors. Teaser: This review highlights the evolving kinase small-molecule drug discovery landscape, and key tenets of the kinase platform at Bristol Myers Squibb to discover the next generation of kinase inhibitors.